- Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Apollomics Announces Presentation at the 2024 BIO International Convention
- Apollomics Announces Private Placement Financing and Addition to Board of Directors
- Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
- Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
- Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
- Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
- Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
More ▼
Key statistics
On Friday, Apollomics Inc (APLM:NAQ) closed at 0.201, 8.41% above its 52-week low of 0.1854, set on Jun 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.2049 |
---|---|
High | 0.21 |
Low | 0.1854 |
Bid | 0.202 |
Offer | 0.22 |
Previous close | 0.2056 |
Average volume | 540.15k |
---|---|
Shares outstanding | 108.66m |
Free float | 47.38m |
P/E (TTM) | -- |
Market cap | 21.84m USD |
EPS (TTM) | -4.34 USD |
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.
More ▼